Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $274250.0.

  • InMed Pharmaceuticals' Accumulated Expenses rose 1503.2% to $274250.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $274250.0, marking a year-over-year increase of 1503.2%. This contributed to the annual value of $490405.0 for FY2025, which is 43.56% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Accumulated Expenses is $274250.0, which was up 1503.2% from $490405.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Accumulated Expenses high stood at $839638.0 for Q2 2022, and its period low was $101775.0 during Q4 2023.
  • Over the past 5 years, InMed Pharmaceuticals' median Accumulated Expenses value was $345350.5 (recorded in 2024), while the average stood at $360849.9.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 3541.2% in 2023, then surged by 23135.45% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Accumulated Expenses stood at $382114.0 in 2021, then soared by 119.73% to $839638.0 in 2022, then crashed by 87.88% to $101775.0 in 2023, then soared by 231.35% to $337236.0 in 2024, then decreased by 18.68% to $274250.0 in 2025.
  • Its Accumulated Expenses stands at $274250.0 for Q3 2025, versus $490405.0 for Q2 2025 and $464665.0 for Q1 2025.